Paclitaxel liposomal - Sun Pharma Advanced Research Company

Drug Profile

Paclitaxel liposomal - Sun Pharma Advanced Research Company

Alternative Names: Liposome-encapsulated paclitaxel - Sun Pharma Advanced Research Company; Paclitaxel injection concentrate for nanodispersion; Paclitaxel nanodispersion - Sun Pharma Advanced Research Company; PICN; SPARC1023; SPARC1028; SPARC1612

Latest Information Update: 02 Nov 2016

Price : $50

At a glance

  • Originator Sun Pharma Advanced Research Company
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer
  • Phase II Solid tumours

Most Recent Events

  • 01 Oct 2016 Sun Pharma completes a phase-I trial in Solid tumours (Combination therapy, Monotherapy, Late-stage disease) in USA (NCT01304303)
  • 22 Jun 2016 Sun Pharma plans a phase I trial for Breast cancer (Late-stage disease, Metastatic disease) in India (CTRI/2016/06/007043)
  • 08 Mar 2016 Sun Pharma terminates a phase I trial in Breast cancer (metastatic disease) in India (NCT02136927)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top